Insights from immuno-oncology: The Society for Immunotherapy of Cancer statement on access to IL-6-targeting therapies for COVID-19
Document Type
Abstract
Publication Date
3-24-2020
Publication Title
Society for Immunotherapy of Cancer (SITC)
Keywords
2019-nCoV
Abstract
The following statement was posted on March 24, 2020 and updated April 2, 2020. It has been accepted for upcoming publication in the Journal for ImmunoTherapy of Cancer (JITC).
Clinical Institute
Cancer
Specialty
Infectious Diseases
Specialty
Oncology
Specialty
Earle A. Chiles Research Institute
Recommended Citation
Ascierto, Paolo A.; Fox, Bernard A; Urba, Walter; Anderson, Ana Carrizosa; Atkins, Michael; Borden, Ernest C.; Brahmer, Julie R.; Butterfield, Lisa H.; Cesano, Alessandra; Chen, Daniel S.; De Gruijl, Tanja D.; Dillman, Robert O.; Drake, Charles G.; Emens, Leisha A.; Gajewski, Thomas F.; Gulley, James L.; Hodi, Jr., F Stephen; Hwu, Patrick; Kaufman, David; Kaufman, Howard L.; Lotze, Michael T.; Marincola, Francesco M.; Margolin, Kim A.; Mastrangelo, Michael J.; Maus, Marcela V.; McNeel, Douglas G.; Parkinson, David R.; Romero, Pedro J.; Sondel, Paul M.; Spranger, Stefani; Sznol, Mario; Weiner, George J.; Wigginton, Jon M.; and Weber, Jeffrey S., "Insights from immuno-oncology: The Society for Immunotherapy of Cancer statement on access to IL-6-targeting therapies for COVID-19" (2020). Articles, Abstracts, and Reports. 2968.
https://digitalcommons.providence.org/publications/2968
